Oncotarget

Reviews:

Rethinking the bile acid/gut microbiome axis in cancer

John P. Phelan, F. Jerry Reen, Jose A. Caparros-Martin, Rosemary O’Connor and Fergal O’Gara _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:115736-115747. https://doi.org/10.18632/oncotarget.22803

Metrics: PDF 954 views  |   HTML 2734 views  |   ?  


Abstract

John P. Phelan1, F. Jerry Reen1, Jose A. Caparros-Martin3, Rosemary O’Connor2 and Fergal O’Gara1,3

1BIOMERIT Research Centre, School of Microbiology, University College Cork - National University of Ireland, Cork, T12 YN60, Ireland

2School of Biochemistry and Cell Biology, University College Cork, National University of Ireland, Cork, T12 YN60, Ireland

3Human Microbiome Programme, School of Biomedical Science, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia

Correspondence to:

Fergal O’Gara, email: f.ogara@ucc.ie

Keywords: bile acids; microbiome; gut-axis; cancer; dysbiosis

Received: June 21, 2017     Accepted: October 27, 2017     Published: December 01, 2017

ABSTRACT

Dietary factors, probiotic agents, aging and antibiotics/medicines impact on gut microbiome composition leading to disturbances in localised microbial populations. The impact can be profound and underlies a plethora of human disorders, including the focus of this review; cancer. Compromised microbiome populations can alter bile acid signalling and produce distinct pathophysiological bile acid profiles. These in turn have been associated with cancer development and progression. Exposure to high levels of bile acids, combined with localised molecular/genome instability leads to the acquisition of bile mediated neoplastic alterations, generating apoptotic resistant proliferation phenotypes. However, in recent years, several studies have emerged advocating the therapeutic benefits of bile acid signalling in suppressing molecular and phenotypic hallmarks of cancer progression. These studies suggest that in some instances, bile acids may reduce cancer phenotypic effects, thereby limiting metastatic potential. In this review, we contextualise the current state of the art to propose that the bile acid/gut microbiome axis can influence cancer progression to the extent that classical in vitro cancer hallmarks of malignancy (cell invasion, cell migration, clonogenicity, and cell adhesion) are significantly reduced. We readily acknowledge the existence of a bile acid/gut microbiome axis in cancer initiation, however, in light of recent advances, we focus exclusively on the role of bile acids as potentially beneficial molecules in suppressing cancer progression. Finally, we theorise that suppressing aggressive malignant phenotypes through bile acid/gut microbiome axis modulation could uncover new and innovative disease management strategies for managing cancers in vulnerable cohorts.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22803